<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83573">
  <stage>Registered</stage>
  <submitdate>8/04/2009</submitdate>
  <approvaldate>17/06/2009</approvaldate>
  <actrnumber>ACTRN12609000479202</actrnumber>
  <trial_identification>
    <studytitle>A randomized, placebo controlled trial of milk products for prevention of gout flares</studytitle>
    <scientifictitle>A randomized, placebo controlled trial of milk products for prevention of gout flares</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gout</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Daily administration of one of three milk products (two intervention milk products plus one control milk product) for three months.  The two intervention products are standard skim milk, and skim milk enriched with milk-derived anti-inflammatory products (Glycomacropeptide [GMP] and G600). Each product will be taken daily as a 250ml drink.</interventions>
    <comparator>Daily administration of a control milk product (lactose) for three months. This product will be taken daily as a 250ml drink.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency of gout flares (requiring treatment), using a gout flare diary</outcome>
      <timepoint>At one, two and three months after the commencement of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of flare pain (10-point Likert scale)</outcome>
      <timepoint>At one, two and three months after the commencement of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient global assessment using a 5-point Likert scale</outcome>
      <timepoint>At one, two and three months after the commencement of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum urate concentration (blood test, standard biochemistry assay)</outcome>
      <timepoint>At one, two and three months after the commencement of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Diagnosis of gout (based on American College of Rheumatology [ACR]criteria) 
2.	At least two gout flares in the last four months
3.	Able to provide written informed consent
4.	Age 18 years and above</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Lactose intolerance
2.	Severe renal impairment (glomerular filtration rate [GFR]&lt;30)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomization by computer</concealment>
    <sequence>Treatment allocations will be randomized by the study statistician, using a variable block size schedule, based on computer-generated random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/03/2009</anticipatedstartdate>
    <actualstartdate>20/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/06/2010</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>LactoPharma Consortium</primarysponsorname>
    <primarysponsoraddress>L 5 Fonterra Centre, 9 Princes Street. 
Private Bag 92032, Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>LactoPharma Consortium</fundingname>
      <fundingaddress>L 5 Fonterra Centre, 9 Princes Street. 
Private Bag 92032, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is three-month study of milk products for prevention of gout attacks.  Patients with recurrent gout attacks will be randomized to three separate milk powder arms; each product will be administered daily as a 250ml milk drink.  The three groups will be a control milk product, a standard skim milk powder, and a skim milk powder enriched with anti-inflammatory factors.  We will analyse whether any of the products tested reduces the frequency of gout attacks.</summary>
    <trialwebsite />
    <publication>http://ard.bmj.com/content/71/6/929.long</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/04/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Bone Research Group Department of Medicine University of Auckland Park Rd Grafton Auckland 1142</address>
      <phone>64 9 3737999 x 82568</phone>
      <fax />
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Anne Horne</name>
      <address>Bone Research Group Department of Medicine University of Auckland Park Rd, Grafton, Auckland 1142</address>
      <phone>64 9 307 8970</phone>
      <fax>64 9 373 7677</fax>
      <email>osteo@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Room 502-201D
Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023
</address>
      <phone>+64 (0) 9 3737999 x82568</phone>
      <fax />
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>